CCO Treatment Updates
Translating Science Into Clinical Practice: Recent Lessons in EGFR Inhibition, Multitargeted TKIs, and the Tumor Microenvironment
Targeting Multiple Pathways in the Treatment of Cancer
|
Module 1 of 4
|
Program Director:
Ezra E. W. Cohen, MD, FRCPC
|
|
 Manuel Hidalgo, MD, PhD, discusses new strategies and ongoing challenges in the development of targeted therapies for cancer. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the challenges associated with developing effective cancer therapies targeting the epidermal growth factor receptor
- Discuss the potential advantages and disadvantages of multitargeted tyrosine kinase inhibitors
- Explain how the tumor microenvironment could be a target for cancer therapy
|
EGFR-Targeted Antibodies: Clinical Applications, Treatment Challenges, and Ongoing Scientific Research
|
Module 2 of 4
|
Program Director:
Ezra E. W. Cohen, MD, FRCPC
- David Cunningham, MD, FRCP
|
|
|
David Cunningham, MD, FRCP, reviews the current use and discusses future applications of EGFR-targeted therapeutic agents used in the treatment of gastrointestinal malignancies. Learning Objectives
Upon completion of this activity, participants should be able to:
- Recall anti-EGFR monoclonal antibodies used to treat gastrointestinal malignancies
- Describe the evaluation of KRAS as a biomarker for efficacy in the setting of colorectal cancer
- Discuss results of recent clinical trials combining anti-EGFR antibodies with chemotherapy for the treatment of gastrointestinal malignancies
- Explain the significance of anti-EGFR antibody–associated acneiform rash
|
Multitargeted Tyrosine Kinase Inhibitors: Clinical Advances, Synergistic Approaches, and Future Development
|
Module 3 of 4
|
Program Director:
Ezra E. W. Cohen, MD, FRCPC
- Ezra E. W. Cohen, MD, FRCPC
|
|
|
Ezra E. W. Cohen, MD, FRCPC, discusses the clinical advances, synergistic approaches and future development of multitargeted tyrosine kinase inhibitors. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the rationale for the use of single-target vs multitargeted tyrosine kinase inhibitors in the treatment of cancer patients
- Review the results of clinical studies involving multitargeted tyrosine kinase inhibitors
- Identify factors useful for the selection of tyrosine kinase inhibitors in specific patient populations
|
Targeting the Tumor Microenvironment: Ongoing Research, Clinical Updates, and Promising Applications (coming soon)
|
Module 4 of 4
|
|
Program Director:
Ezra E. W. Cohen, MD, FRCPC
|
|
Allan Lipton, MD, discusses recent data on current therapeutic approaches in the prevention of skeletal complications associated with bone metastases in cancer patients. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the incidence of bone metastases and their associated complications in several different cancers
- Articulate the role of the RANKL/RANK cytokine system in the bone microenvironment and the formation of osteolytic metastases
- Summarize recent data relating to the efficacy of targeting RANKL in cancer patients with metastases to the bone
|
CCO Slidesets
Targeting Multiple Pathways in the Treatment of Cancer
 |
|
Manuel Hidalgo, MD, PhD, gives a brief overview of the current state-of-the-art with monoclonal antibodies and multitargeted tyrosine kinase inhibitors as antitumor therapies.
Format: Microsoft PowerPoint (.ppt) | File size: 2,047 KB
|
EGFR-Targeted Antibodies: Clinical Applications, Treatment Challenges, and Ongoing Scientific Research
 |
|
David Cunningham, MD, FRCP discusses the rationale for targeting the EGFR with monoclonal antibodies and gives an update on their use in gastrointestinal cancers as monotherapy and in combination with chemotherapies.
Format: Microsoft PowerPoint (.ppt) | File size: 6,534 KB
|
Multitargeted Tyrosine Kinase Inhibitors: Clinical Advances, Synergistic Approaches, and Future Development
 |
|
Ezra Cohen MD, FRCPC, gives an update on the use of multitargeted tyrosine kinase inhibitors approved for the treatment of a variety of cancers, and provides an overview of mTKIs in clinical development.
Format: Microsoft PowerPoint (.ppt) | File size: 2,132 KB
|
Targeting the Tumor Microenvironment: Ongoing Research, Clinical Updates and Promising Applications
 |
|
Allan Lipton, MD, reviews current and emerging management strategies for cancer patients with bone metastases.
Format: Microsoft PowerPoint (.ppt) | File size: 1,568 KB
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|